[ARDX] Ardelyx, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 14.6 Change: 1.2 (8.96%)
Ext. hours: Change: 0 (0%)

chart ARDX

Refresh chart

Strongest Trends Summary For ARDX

ARDX is in the medium-term down -54% in 7 months. In the long-term down -69% below S&P in 1 year and down -87% below S&P in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Ardelyx, Inc. discovers, develops, and commercializes non-systemic small molecule therapeutics for the gastrointestinal tract to treat cardio-renal and metabolic diseases. Its lead product candidate is Tenapanor, a small molecule, orally administered inhibitor of NHE3, which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. The company also evaluates small molecule NaP2b inhibitors for the treatment of hyperphosphatemia in end stage renal disease. In addition, its other discovery and lead development programs consist of RDX009, RDX013, and RDX020 programs that are in research phase focusing on cardio-renal and metabolic diseases. It has a collaboration partnership agreement with AstraZeneca AB for the development and commercialization of tenapanor. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was founded in 2007 an

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-2.73 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -35.61% Sales Growth - Q/Q-7.19% P/E-1.59
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-3.46% ROE-6.28% ROI
Current Ratio5.12 Quick Ratio Long Term Debt/Equity Debt Ratio0.34
Gross Margin Operating Margin-15.85% Net Profit Margin-12.59% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities300 K Cash From Investing Activities-1.05 M Cash From Operating Activities-8.21 M Gross Profit
Net Profit-3.5 M Operating Profit-3.49 M Total Assets105.4 M Total Current Assets101.91 M
Total Current Liabilities19.91 M Total Debt Total Liabilities47.4 M Total Revenue5.88 M
Technical Data
High 52 week7.9 Low 52 week1.66 Last close2.23 Last change-4.29%
RSI69.29 Average true range0.19 Beta1.5 Volume61.04 K
Simple moving average 20 days10.4% Simple moving average 50 days-8.8% Simple moving average 200 days-41.66%
Performance Data
Performance Week-7.08% Performance Month3.72% Performance Quart-39.89% Performance Half-52.04%
Performance Year-68.59% Performance Year-to-date24.58% Volatility daily5.5% Volatility weekly12.3%
Volatility monthly25.21% Volatility yearly87.35% Relative Volume187.64% Average Volume352.07 K
New High New Low

News

2019-03-19 17:38:31 | East Bay company's drug may shrink dialysis patient 'pill burden.' But will it help them live longer?

2019-03-14 17:00:00 | Ardelyx Appoints Renowned Nephrologist, Geoffrey A. Block, M.D., to Its Board of Directors

2019-03-07 17:00:00 | Ardelyx Announces Peer-Reviewed Publication of Positive Phase 3 Results of Tenapanor for the Treatment of Hyperphosphatemia in the Journal of the American Society of Nephrology

2019-03-06 16:05:00 | Ardelyx Reports Fourth Quarter 2018 Financial Results and Recent Highlights

2019-03-01 14:54:24 | An Examination Of Ardelyx, Inc. NASDAQ:ARDX

2019-02-21 08:00:00 | Ardelyx to Participate in Leerink Partners 8th Annual Global Healthcare Conference

2019-02-12 08:25:00 | Factors of Influence in 2019, Key Indicators and Opportunity within Park Hotels & Resorts, Planet Fitness, Aevi Genomic Medicine, Ardelyx, AMERISAFE, and inTest — New Research Emphasizes Economic Growth

2019-02-07 06:30:00 | Ardelyx Collaboration Partner, Kyowa Hakko Kirin, Announces Initiation of a Phase 2 Clinical Study of Tenapanor for Hyperphosphatemia Patients on Dialysis in Japan

2019-01-18 09:20:26 | Ardelyx, Inc. NASDAQ:ARDX Is Trading At A 28.78% Discount

2018-12-18 02:50:44 | Ardelyx Inc ARDX: Are Hedge Funds Right About This Stock?

2018-11-26 14:26:07 | What Type Of Shareholder Owns Ardelyx Inc’s NASDAQ:ARDX?

2018-11-13 08:30:00 | Ardelyx Announces FDA Acceptance of the Filing of its New Drug Application for Tenapanor for the Treatment of Patients with IBS-C

2018-11-07 18:12:34 | Ardelyx: 3Q Earnings Snapshot

2018-11-07 16:05:00 | Ardelyx Reports Third Quarter 2018 Financial Results and Recent Highlights

2018-10-26 13:01:00 | Ardelyx Presents New Preclinical Data Demonstrating Synergy between Tenapanor and Sevelamer When Dosed in Combination for Elevated Serum Phosphorus

2018-10-16 07:50:00 | Analysis: Positioning to Benefit within Ardelyx, AXT, TG Therapeutics, MarineMax, Oclaro, and BioCryst Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results

2018-10-08 08:01:00 | Ardelyx Showcases New Data from T3MPO-3 Long-Term Safety Trial of Tenapanor for IBS-C in Presidential Poster at ACG 2018 Annual Meeting

2018-10-04 06:30:00 | Ardelyx to Host Its First Annual Investor Day Focused on Treatment Landscape of Renal Disorders

2018-09-18 08:19:01 | How Does Investing In Ardelyx Inc NASDAQ:ARDX Impact Your Portfolio?

2018-09-13 06:30:00 | Ardelyx Submits New Drug Application for U.S. Marketing Authorization of Tenapanor for IBS-C to U.S. Food and Drug Administration

2018-08-29 14:16:00 | Ardelyx Announces Science Translational Medicine Publication Detailing Tenapanor's Unique Mechanism of Action Inhibiting Paracellular Phosphate Absorption

2018-08-17 08:20:00 | Consolidated Research: 2018 Summary Expectations for PDF Solutions, MYOS RENS Technology, Aldeyra Therapeutics, The Ensign Group, Everi, and Ardelyx — Fundamental Analysis, Key Performance Indications

2018-08-16 15:06:47 | Edited Transcript of ARDX earnings conference call or presentation 7-Aug-18 8:30pm GMT

2018-08-07 16:51:35 | Ardelyx: 2Q Earnings Snapshot

2018-08-07 16:01:00 | Ardelyx Reports Second Quarter 2018 Financial Results and Recent Highlights

2018-08-07 14:30:00 | Ardelyx, Inc. to Host Earnings Call

2018-08-01 06:30:00 | Ardelyx Announces Date of Second Quarter 2018 Financial Results and Conference Call

2018-06-26 07:10:00 | Free Technical Reports on Array BioPharma and Three Additional Biotech Equities

2018-05-31 07:40:00 | Consolidated Research: 2018 Summary Expectations for CorVel, Consol Energy, Ardelyx, Aevi Genomic Medicine, Proofpoint, and Brink's — Fundamental Analysis, Key Performance Indications

2018-05-29 06:30:00 | Ardelyx to Present at the Jefferies 2018 Global Healthcare Conference

2018-05-23 13:39:00 | Why Ardelyx Inc. Is Down by Double Digits for a Second Day in a Row

2018-05-23 08:15:53 | Benzinga's Daily Biotech Pulse: Insmed Presents Data, Pfenex Pulls Back On Offering, Oncolytics Listing

2018-05-22 18:00:00 | Ardelyx Announces Pricing of Public Offering of Common Stock

2018-05-22 08:05:40 | Benzinga's Daily Biotech Pulse: Melinta, Ardelyx Pull Back On Offerings, Insys Awaits FDA Verdict

2018-05-21 16:02:00 | Ardelyx Raises $50 Million in Loan Agreement with Solar Capital and Bridge Bank

2018-05-21 16:01:00 | Ardelyx Announces Proposed Public Offering of Common Stock

2018-05-08 17:56:31 | Ardelyx: 1Q Earnings Snapshot

2018-05-08 16:05:00 | Ardelyx Reports First Quarter 2018 Financial Results and Recent Business Highlights

2018-04-05 08:15:00 | Analysis: Positioning to Benefit within Euronet Worldwide, Innospec, Zosano Pharma, Ardelyx, Crown Castle International, and Aldeyra Therapeutics — Research Highlights Growth, Revenue, and Consolidated Results

2018-03-19 06:30:00 | Ardelyx and Knight Collaborate to Bring Tenapanor to Patients in Canada

2018-03-14 16:34:31 | Ardelyx posts 4Q profit

2018-03-14 16:05:00 | Ardelyx Reports 2017 Financial Results and Appoints Industry Veteran, Jan Lundberg, Ph.D., to Board of Directors

2018-02-26 08:20:00 | Consolidated Research: 2018 Summary Expectations for Progress Software, Cracker Barrel Old Country Store, Natural Grocers by Vitamin Cottage, VBI Vaccines, Ardelyx, and CytomX Therapeutics — Fundamental Analysis, Key Performance Indications

2018-02-12 06:30:00 | Ardelyx Announces Departure of Chief Scientific Officer

2018-02-08 06:30:00 | Ardelyx to Participate in Leerink Partners 7th Annual Global Healthcare Conference

2018-02-02 11:02:20 | Best NasdaqGM Growth Stocks

2018-01-29 13:40:00 | 5 Great Breakout Stocks Offering Superlative Returns

2018-01-19 08:20:01 | Zacks.com highlights: Sanchez Midstream Partners, Tecnoglass, Aeterna Zentaris, Ardelyx and Matrix Service

2018-01-18 09:32:02 | 5 Great Breakout Stocks Offering Superlative Returns

2018-01-04 05:03:10 | Can The Uptrend Continue for Ardelyx ARDX?